Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOAL-ARC: Golimumab dose optimisation to achieve response in ulcerative colitis
2015-004724-62Phase 4Terminated
- Sponsor
- UCB
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of golimumab in autoimmune colitis, sponsored by UCB. Primary endpoint: Patient Continuous Clinical Response (pCCR). Started Nov 2015; status: terminated.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-004724-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004724-62.